Crystalline forms of therapeutic compounds and uses thereof
Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
1. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition comprising:
a crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at about 8-9 degrees 2θ, about 10.5-11.5 degrees 2θ, and about 18-19 degrees 2θ; and
at least one pharmaceutically acceptable excipient.
2. The method of claim 1 , wherein the disease is an ocular disease.
3. The method of claim 1 , wherein the disease is retinopathy.
4. The method of claim 1 , wherein the disease is age-related macular degeneration (AMD).
5. The method of claim 1 , wherein the disease is corneal neovascularization.
6. The method of claim 1 , wherein the crystalline form is an anhydrate.
7. A method of inhibiting growth factor signaling comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition comprising:
a crystalline form of Compound 1:
wherein the crystalline form has an XRPD pattern comprising peaks at about 8-9 degrees 2θ, about 10.5-11.5 degrees 2θ, and about 18-19 degrees 2θ; and
at least one pharmaceutically acceptable excipient.
8. The method of claim 7 , wherein the crystalline form is an anhydrate.